Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oragenics Inc OGEN

Healthcare Biotechnology
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for... see more

Recent & Breaking News (NYSEAM:OGEN)

Oragenics Announces Closing of $6.5 Million Registered Direct Offering

Business Wire December 29, 2020

Oragenics, Inc. Announces $6.5 Million Registered Direct Offering

Business Wire December 24, 2020

Oragenics Announces Closing of $6.0 Million Underwritten Public Offering

Business Wire November 24, 2020

Oragenics Prices $5.25 Million Common Stock Offering

Business Wire November 20, 2020

CORRECTING AND REPLACING Oragenics Announces Proposed Underwritten Public Offering

Business Wire November 19, 2020

Organics Announces Proposed Underwritten Public Offering

Business Wire November 19, 2020

FDA Broadly Supports Oragenics' Pre-IND Development Program for its SARS-CoV-2 Vaccine

Business Wire October 6, 2020

Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine

Business Wire September 28, 2020

Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference

Business Wire September 11, 2020

Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine

Business Wire August 20, 2020

Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies

Business Wire July 22, 2020

Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program

Business Wire July 10, 2020

Oragenics, Inc. to Present at the June 2020 Virtual Summer Investor Summit

Business Wire June 4, 2020

47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

Accesswire June 3, 2020

Oragenics Inc. and Aragen Bioscience Enter Agreement to Accelerate Development of TerraCoV2, a SARS-CoV-2 (COVID 19) Vaccine Candidate

Business Wire May 19, 2020

Oragenics Announces New Member of the Board of Directors

Business Wire May 4, 2020

Oragenics Acquires Noachis Terra Inc., To Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing "Spike Protein"

Business Wire May 4, 2020

Oragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer

Business Wire April 15, 2020

Oragenics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

Business Wire February 7, 2020

Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019

Business Wire December 3, 2019